Endotype-guided medical therapy and symptom response in ANOCA
EuroIntervention · 2026-07 · 22 (14) · e784-e794
DOI: 10.4244/eij-d-26-00148 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift EuroIntervention, 2026-07. Verfasst von Jacopo Farina und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy. Hauptthemen laut MEDLINE: Angina Pectoris, Coronary Vessels, Coronary Artery Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Invasive coronary functional testing enables the classification of angina with non-obstructive coronary arteries (ANOCA) into distinct endotypes. However, real-world data linking endotype identification to subsequent pharmacological management and patient-reported symptom outcomes remain limited. AIMS: We sought to evaluate the association between coronary endotypes, post-testing pharmacological treatment patterns, and changes in angina-related quality of life in patients with ANOCA in a multicentre real-world registry. METHODS: Consecutive ANOCA patients undergoing invasive coronary functional testing were included. Patients were classified into six endotypes using adenosine- and acetylcholine-based testing. Pharmacological therapy was adjusted at the discretion of the treating physician based on the functional test results. The primary endpoint was a clinically meaningful improvement in angina-related health status, defined as a ≥5-point increase in the 7-item Seattle Angina Questionnaire (SAQ-7) summary score, assessed within each endotype. RESULTS: Among 525 patients, endotype distribution was as follows: normal physiology 10.5%, elevated resting coronary blood flow 8.8%, high resistance 13.9%, compensated high resistance 14.9%, epicardial spasm 33.3%, and microvascular spasm 18.7%. After testing, prescription patterns differed across the endotypes, with increased use of beta blockers, ranolazine, and renin-angiotensin-aldosterone system blockers in coronary microvascular dysfunction endotypes and greater use of non-dihydropyridine calcium channel blockers in vasospastic endotypes. At follow-up, a ΔSAQ-7 summary score ≥5 points was observed in elevated resting flow, high-resistance, compensated high-resistance, and epicardial spasm endotypes (all p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
- Department of Cardiology, Creighton University School of Medicine, Phoenix, AZ, USA.
- Hospital Clínic, Cardiovascular Clinic Institute, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
- Maasstad Hospital, Rotterdam, the Netherlands.
- IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, D.C., USA.
Zitieren
APA
Farina, J., Kumar, S., Campo, G., Biscaglia, S., Sarti, A., Llevadot-Sesmilo, J., Paradies, V., Mincione, G., Case, B. C., Leone, A. M., Galante, D., Erriquez, A., & Brugaletta, S. (2026). Endotype-guided medical therapy and symptom response in ANOCA. EuroIntervention, 22(14), e784-e794. https://doi.org/10.4244/eij-d-26-00148
Vancouver
Farina J, Kumar S, Campo G, Biscaglia S, Sarti A, Llevadot-Sesmilo J, et al. Endotype-guided medical therapy and symptom response in ANOCA. EuroIntervention. 2026;22(14):e784-e794. doi:10.4244/eij-d-26-00148
BibTeX
@article{Farina2026,
author = {Farina, Jacopo and Kumar, Sant and Campo, Gianluca and Biscaglia, Simone and Sarti, Alberto and Llevadot-Sesmilo, Joan and Paradies, Valeria and Mincione, Gianluca and Case, Brian Christopher and Leone, Antonio Maria and Galante, Domenico and Erriquez, Andrea and Brugaletta, Salvatore},
title = {Endotype-guided medical therapy and symptom response in ANOCA},
journal = {EuroIntervention},
year = {2026},
volume = {22},
number = {14},
pages = {e784--e794},
doi = {10.4244/eij-d-26-00148}
}
EUVIMED